[{"id":"65fa5200-d596-487d-929e-1fa05dc863a1","acronym":"NRG-GY007","url":"https://clinicaltrials.gov/study/NCT02713386","created_at":"2021-01-18T13:15:58.271Z","updated_at":"2025-02-25T12:26:27.453Z","phase":"Phase 1/2","brief_title":"Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT02713386 - NRG-GY007","lead_sponsor":"NRG Oncology","biomarkers":" BRCA1 • BRCA2 • BRCA • CRP","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • BRCA • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Jakafi (ruxolitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 147","initiation":"Initiation: 11/14/2016","start_date":" 11/14/2016","primary_txt":" Primary completion: 09/30/2021","primary_completion_date":" 09/30/2021","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2025-02-24"},{"id":"67ef8418-6d77-4d74-95d8-80f63ef20ed4","acronym":"SWOG S2001","url":"https://clinicaltrials.gov/study/NCT04548752","created_at":"2021-01-18T21:45:16.998Z","updated_at":"2025-02-25T12:27:43.236Z","phase":"Phase 2","brief_title":"Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations","source_id_and_acronym":"NCT04548752 - SWOG S2001","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib) • cisplatin • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 02/22/2021","start_date":" 02/22/2021","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2025-02-24"},{"id":"5ca3f586-5d57-495c-9088-bac9d19c4782","acronym":"","url":"https://clinicaltrials.gov/study/NCT04826341","created_at":"2021-04-01T16:52:34.686Z","updated_at":"2025-02-25T13:40:26.267Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors","source_id_and_acronym":"NCT04826341","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • HRD • CDK12 • BRCA • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A","pipe":" | ","alterations":" ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation","tags":["BRCA1 • BRCA2 • HRD • CDK12 • BRCA • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620) • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 09/20/2021","start_date":" 09/20/2021","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2025-02-21"},{"id":"7db8cbc0-f928-4935-a5eb-7dd8dd21f64b","acronym":"EA2192","url":"https://clinicaltrials.gov/study/NCT04858334","created_at":"2021-04-26T13:52:59.130Z","updated_at":"2025-02-25T13:40:27.622Z","phase":"Phase 2","brief_title":"APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation","source_id_and_acronym":"NCT04858334 - EA2192","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" PALB2 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PALB2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 152","initiation":"Initiation: 06/22/2021","start_date":" 06/22/2021","primary_txt":" Primary completion: 10/31/2027","primary_completion_date":" 10/31/2027","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2025-02-21"},{"id":"aae6b561-f8a6-4a7b-8a1a-ca992b0769d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00006421","created_at":"2021-01-17T23:53:44.292Z","updated_at":"2025-02-25T13:38:43.830Z","phase":"","brief_title":"Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study","source_id_and_acronym":"NCT00006421","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"],"overall_status":"Completed","enrollment":" Enrollment 200","initiation":"Initiation: 10/25/2000","start_date":" 10/25/2000","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-21"},{"id":"4cc7d5ae-d434-4c5a-bf92-880e3c64f923","acronym":"NCI-2016-01130","url":"https://clinicaltrials.gov/study/NCT02849496","created_at":"2021-01-18T13:59:18.008Z","updated_at":"2025-02-25T13:52:10.914Z","phase":"Phase 2","brief_title":"Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer","source_id_and_acronym":"NCT02849496 - NCI-2016-01130","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • TMB • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" HER-2 positive • BRCA mutation","tags":["HER-2 • TMB • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Tecentriq (atezolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 03/30/2017","start_date":" 03/30/2017","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2025-02-20"},{"id":"5eb63239-f0c2-440d-925c-994f2877adc9","acronym":"","url":"https://clinicaltrials.gov/study/NCT00740805","created_at":"2021-01-18T02:47:51.919Z","updated_at":"2025-02-25T13:47:58.987Z","phase":"Phase 1","brief_title":"Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT00740805","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR • BRCA1 • BRCA","pipe":" | ","alterations":" HER-2 negative • BRCA mutation","tags":["HER-2 • ER • PGR • BRCA1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • veliparib (ABT-888) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 08/18/2008","start_date":" 08/18/2008","primary_txt":" Primary completion: 09/03/2021","primary_completion_date":" 09/03/2021","study_txt":" Completion: 10/22/2025","study_completion_date":" 10/22/2025","last_update_posted":"2025-02-20"},{"id":"2da5468a-79d4-4eeb-942f-5b05fa2fb4d8","acronym":"CERTIS1","url":"https://clinicaltrials.gov/study/NCT05417594","created_at":"2022-06-14T22:56:26.797Z","updated_at":"2025-02-25T14:08:54.388Z","phase":"Phase 1/2","brief_title":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","source_id_and_acronym":"NCT05417594 - CERTIS1","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • HRD • BRCA • RAD51C • RAD51D","pipe":" | ","alterations":" HER-2 negative • PALB2 mutation • RAD51C mutation • RAD51D mutation","tags":["HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • HRD • BRCA • RAD51C • RAD51D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PALB2 mutation • RAD51C mutation • RAD51D mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Enhertu (fam-trastuzumab deruxtecan-nxki) • Datroway (datopotamab deruxtecan-dlnk) • AZD9574"],"overall_status":"Recruiting","enrollment":" Enrollment 490","initiation":"Initiation: 06/24/2022","start_date":" 06/24/2022","primary_txt":" Primary completion: 08/28/2026","primary_completion_date":" 08/28/2026","study_txt":" Completion: 08/28/2026","study_completion_date":" 08/28/2026","last_update_posted":"2025-02-19"},{"id":"94997e45-2dee-4e97-9985-6f9da960c39e","acronym":"BROCADE3","url":"https://clinicaltrials.gov/study/NCT02163694","created_at":"2021-01-17T17:32:00.170Z","updated_at":"2025-02-25T14:06:48.816Z","phase":"Phase 3","brief_title":"A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer","source_id_and_acronym":"NCT02163694 - BROCADE3","lead_sponsor":"AbbVie","biomarkers":" HER-2 • BRCA1 • BRCA2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • veliparib (ABT-888)"],"overall_status":"Completed","enrollment":" Enrollment 513","initiation":"Initiation: 04/08/2014","start_date":" 04/08/2014","primary_txt":" Primary completion: 04/05/2019","primary_completion_date":" 04/05/2019","study_txt":" Completion: 01/25/2024","study_completion_date":" 01/25/2024","last_update_posted":"2025-02-19"},{"id":"f7e6df94-a121-41c2-ab20-30322990863a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05327010","created_at":"2022-04-14T12:53:52.597Z","updated_at":"2025-02-25T14:02:49.505Z","phase":"Phase 2","brief_title":"Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial","source_id_and_acronym":"NCT05327010","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRCA1 • BRCA2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • BARD1","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12 • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation","tags":["KRAS • BRCA1 • BRCA2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • BARD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12 • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • ZEN-3694"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 11/14/2022","start_date":" 11/14/2022","primary_txt":" Primary completion: 08/04/2025","primary_completion_date":" 08/04/2025","study_txt":" Completion: 08/04/2025","study_completion_date":" 08/04/2025","last_update_posted":"2025-02-19"},{"id":"78af9b6a-0b92-4e92-b86c-385f5f7643c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04266912","created_at":"2021-01-18T20:43:57.460Z","updated_at":"2025-02-25T14:15:34.609Z","phase":"Phase 1/2","brief_title":"Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors","source_id_and_acronym":"NCT04266912","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • BRCA2 • ATM • ARID1A • BAP1 • MSH2 • CDK12 • ATRX • CHEK2 • SMARCB1 • RAD51 • FANCA • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • ATM • ARID1A • BAP1 • MSH2 • CDK12 • ATRX • CHEK2 • SMARCB1 • RAD51 • FANCA • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • berzosertib (M6620)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/17/2020","start_date":" 03/17/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-18"},{"id":"b7c5654f-af40-4901-bb91-a92eb186ae23","acronym":"TURBO","url":"https://clinicaltrials.gov/study/NCT06111417","created_at":"2023-11-01T15:12:33.488Z","updated_at":"2025-02-25T14:10:16.182Z","phase":"","brief_title":"Use of an Ultra-rapid BRCA1/2 Status Screening Test in Theranostic Indication: Performance and Interest for Patients and Practitioners","source_id_and_acronym":"NCT06111417 - TURBO","lead_sponsor":"Centre Georges Francois Leclerc","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 06/12/2024","start_date":" 06/12/2024","primary_txt":" Primary completion: 06/12/2026","primary_completion_date":" 06/12/2026","study_txt":" Completion: 08/12/2026","study_completion_date":" 08/12/2026","last_update_posted":"2025-02-18"},{"id":"48f5abe6-9ec9-4e35-ad4a-60d366e60af6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03598257","created_at":"2021-01-18T17:41:27.688Z","updated_at":"2025-02-25T14:15:11.919Z","phase":"Phase 2","brief_title":"Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer","source_id_and_acronym":"NCT03598257","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • PGR • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["ER • PGR • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 01/18/2019","start_date":" 01/18/2019","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-17"},{"id":"aabfe14b-2567-4902-bc32-9cee3990645a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03317405","created_at":"2021-01-18T16:22:58.685Z","updated_at":"2025-02-25T14:39:46.434Z","phase":"Phase 1","brief_title":"Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery","source_id_and_acronym":"NCT03317405","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zonalta (Z-endoxifen hydrochloride)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 10/31/2018","start_date":" 10/31/2018","primary_txt":" Primary completion: 02/22/2021","primary_completion_date":" 02/22/2021","study_txt":" Completion: 08/16/2025","study_completion_date":" 08/16/2025","last_update_posted":"2025-02-14"},{"id":"5bdc28e5-7ca8-447b-ae67-6e292adebde6","acronym":"TRIFOUR","url":"https://clinicaltrials.gov/study/NCT05181462","created_at":"2022-01-06T22:53:40.626Z","updated_at":"2025-02-25T15:12:31.656Z","phase":"Phase 1/2","brief_title":"Nadunolimab in Combination with Gemcitabine Plus Carboplatin in Patients with Advanced Triple Negative Breast Cancer.","source_id_and_acronym":"NCT05181462 - TRIFOUR","lead_sponsor":"Cantargia AB","biomarkers":" HER-2 • PD-L1 • ER • PGR • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" HER-2 negative • HER-2 negative + HR negative • HER-2 negative + HR negative + BRCA mutation","tags":["HER-2 • PD-L1 • ER • PGR • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 negative + HR negative • HER-2 negative + HR negative + BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • nadunolimab (CAN04)"],"overall_status":"Recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 01/11/2022","start_date":" 01/11/2022","primary_txt":" Primary completion: 06/15/2025","primary_completion_date":" 06/15/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2025-02-13"},{"id":"4a93fa9c-cccb-4098-a7be-8644c6938000","acronym":"SOLO-1","url":"https://clinicaltrials.gov/study/NCT01844986","created_at":"2021-01-17T17:30:05.211Z","updated_at":"2025-02-25T15:17:06.143Z","phase":"Phase 3","brief_title":"Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.","source_id_and_acronym":"NCT01844986 - SOLO-1","lead_sponsor":"AstraZeneca","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • cisplatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 450","initiation":"Initiation: 08/26/2013","start_date":" 08/26/2013","primary_txt":" Primary completion: 05/17/2018","primary_completion_date":" 05/17/2018","study_txt":" Completion: 08/29/2028","study_completion_date":" 08/29/2028","last_update_posted":"2025-02-12"},{"id":"87a9c1fe-92c6-4692-b3ba-4b7c76aefe9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02993068","created_at":"2021-01-18T14:43:23.226Z","updated_at":"2025-02-25T15:17:22.718Z","phase":"","brief_title":"Stand Up to Cancer: MAGENTA (Making Genetic Testing Accessible)","source_id_and_acronym":"NCT02993068","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER • PGR • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • BRIP1 • RAD51C • RAD51D • BARD1","pipe":" | ","alterations":" PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation","tags":["ER • PGR • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • BRIP1 • RAD51C • RAD51D • BARD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation"],"overall_status":"Suspended","enrollment":" Enrollment 5200","initiation":"Initiation: 04/18/2017","start_date":" 04/18/2017","primary_txt":" Primary completion: 04/18/2026","primary_completion_date":" 04/18/2026","study_txt":" Completion: 04/18/2026","study_completion_date":" 04/18/2026","last_update_posted":"2025-02-12"},{"id":"e94eda48-02c6-40bc-8f38-bdeb553754b5","acronym":"CASE6119","url":"https://clinicaltrials.gov/study/NCT04674306","created_at":"2021-01-19T20:45:27.933Z","updated_at":"2025-02-25T15:18:56.819Z","phase":"Phase 1","brief_title":"Adjuvant Therapy with an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer","source_id_and_acronym":"NCT04674306 - CASE6119","lead_sponsor":"George T. Budd","biomarkers":" HER-2 • ER • PGR • BRCA1 • PRL","pipe":" | ","alterations":" HER-2 negative • PALB2 mutation • ER negative","tags":["HER-2 • ER • PGR • BRCA1 • PRL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PALB2 mutation • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e alpha-lactalbumin vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2025-02-12"},{"id":"63139aa8-19bf-4602-a810-5c7110a10962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04423185","created_at":"2021-01-18T21:18:39.174Z","updated_at":"2025-02-25T15:26:22.079Z","phase":"Phase 2","brief_title":"PLATFORM Study of Precision Medicine for Rare Tumors","source_id_and_acronym":"NCT04423185","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification","tags":["EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 770","initiation":"Initiation: 08/15/2020","start_date":" 08/15/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-11"},{"id":"a5404254-66c2-4fcb-a900-67628fac7462","acronym":"","url":"https://clinicaltrials.gov/study/NCT03296826","created_at":"2021-01-18T16:17:05.149Z","updated_at":"2025-02-25T15:25:39.354Z","phase":"","brief_title":"Prospective Cohort Study of Germline Variant Carriers with BRCA1 or BRCA2","source_id_and_acronym":"NCT03296826","lead_sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • BRCA"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 11/08/2017","start_date":" 11/08/2017","primary_txt":" Primary completion: 03/31/2032","primary_completion_date":" 03/31/2032","study_txt":" Completion: 03/31/2032","study_completion_date":" 03/31/2032","last_update_posted":"2025-02-11"},{"id":"bc1b58c1-b1d8-4700-b8ba-84e1753bb5a8","acronym":"PRECEDE","url":"https://clinicaltrials.gov/study/NCT04970056","created_at":"2021-07-21T13:52:39.762Z","updated_at":"2025-02-25T15:26:58.339Z","phase":"","brief_title":"Pancreatic Cancer Early Detection Consortium","source_id_and_acronym":"NCT04970056 - PRECEDE","lead_sponsor":"Arbor Research Collaborative for Health","biomarkers":" BRCA1 • BRCA2 • STK11 • CDKN2A • MLH1 • MSH6 • MSH2","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • STK11 • CDKN2A • MLH1 • MSH6 • MSH2"],"overall_status":"Recruiting","enrollment":" Enrollment 10000","initiation":"Initiation: 09/18/2020","start_date":" 09/18/2020","primary_txt":" Primary completion: 12/31/2030","primary_completion_date":" 12/31/2030","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-02-11"},{"id":"60bce1a2-b876-426c-a77f-15b4b5b443a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03805919","created_at":"2021-01-18T18:48:39.011Z","updated_at":"2025-02-25T15:34:18.012Z","phase":"","brief_title":"Men at High Genetic Risk for Prostate Cancer","source_id_and_acronym":"NCT03805919","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD51D • EPCAM • NBN • FANCF • FANCL • FANCI • FANCM • FANCD2 • FANCE • FANCG • FANCB • FANCC • HOXB13","pipe":"","alterations":" ","tags":["TP53 • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD51D • EPCAM • NBN • FANCF • FANCL • FANCI • FANCM • FANCD2 • FANCE • FANCG • FANCB • FANCC • HOXB13"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 03/27/2019","start_date":" 03/27/2019","primary_txt":" Primary completion: 01/01/2029","primary_completion_date":" 01/01/2029","study_txt":" Completion: 01/01/2039","study_completion_date":" 01/01/2039","last_update_posted":"2025-02-10"},{"id":"79754c99-3751-46a3-9cbb-21442fd0c3e5","acronym":"NRG-GY023","url":"https://clinicaltrials.gov/study/NCT04739800","created_at":"2021-02-05T13:56:26.400Z","updated_at":"2025-02-25T15:26:41.757Z","phase":"Phase 2","brief_title":"Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents","source_id_and_acronym":"NCT04739800 - NRG-GY023","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["PD-L1 • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lynparza (olaparib) • Imfinzi (durvalumab) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 06/10/2021","start_date":" 06/10/2021","primary_txt":" Primary completion: 01/26/2023","primary_completion_date":" 01/26/2023","study_txt":" Completion: 06/14/2025","study_completion_date":" 06/14/2025","last_update_posted":"2025-02-10"},{"id":"45b2704f-6ced-4f5c-956f-04b2574840c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04543903","created_at":"2024-01-03T15:17:28.791Z","updated_at":"2025-02-25T16:32:13.553Z","phase":"","brief_title":"Neoadjuvant Interstitial Brachytherapy Using Diffusing Alpha Emitters Radiation Therapy in Men With Prostate Cancer","source_id_and_acronym":"NCT04543903","lead_sponsor":"Alpha Tau Medical LTD.","biomarkers":" BRCA1 • CD34 • XRCC2","pipe":"","alterations":" ","tags":["BRCA1 • CD34 • XRCC2"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 05/16/2022","start_date":" 05/16/2022","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2025-02-07"}]